Department of Hematology;
Key Laboratory of Cancer Prevention and Therapy;
Tianjin Medical University Cancer Institute and Hospital;
National Clinical Research Center for Cancer;
Tianjin Clinical Research Center for Cancer;
Tianjin 300000;
China;
Department of Oncology;
Second Hospital of Tianjin Medical University;
Institute of Urology Tianjin;
Tianjin 300000;
China;
Multiple myeloma; 1q21 gain; Poor prognosis; Drug resistance;